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ABSTRACT
To determine the extent to which post-hypoglycaemic
patients with diabetes, who are prescribed oral hypogly-
caemic agents (OHA) are at risk of repeat hypoglycaemic
events (RHE) after being treated in the prehospital
environment and whether they should be transported to
hospital regardless of their post-treatment response, a
systematic literature review was carried out using an
overlapping retrieval strategy that included both published
and unpublished literature. Retrieved papers were
reviewed by each author for inclusion. Disagreements
regarding inclusion were resolved through discussion.
Ninety-eight papers and other relevant material were
retrieved using the developed search strategy. Twenty-
three papers and other relevant material were included in
the final review. A narrative synthesis of the findings is
presented. Although several case reports demonstrate the
risks associated with repeat or prolonged hypoglycaemia,
the review was unable to locate any specific high quality
research in this area. Consequently, caution is required in
interpreting the findings of the studies. Post-hypoglycae-
mic patients treated in the prehospital environment have
a 2–7% risk of experiencing a RHE within 48 h. The
literature retrieved in this study recognises the potential
for OHA to cause RHE. However, the extent to which this
occurs in practice remains unknown. This lack of evidence
has led to the recommendation that conservative
management, through admission to hospital, is appro-
priate. The review concludes with recommendations for
both practice and research.
Diabetes is a growing health concern placing
increasing pressure on NHS resources.1 In the UK
2.3 million people are currently diagnosed with the
condition; a figure predicted to rise to 3 million by
the end of the decade.2 Audit data from one of the
UK’s largest ambulance services indicate that
approximately 50% of the 6500 diabetes-related
emergency calls per annum were for patients with
hypoglycaemia. (R Lawrenson, Scottish
Ambulance Service Audit Manager, personal com-
munication, 2008).
In response to continuing increases in emergency
department admissions,3 UK ambulance services
have identified new ways of working aimed at
reducing unnecessary transportations and atten-
dances at emergency departments. Initiatives such
as ‘‘treat and refer’’ or ‘‘see and treat’’ (S&T)
guidelines have enabled ambulance clinicians to
attend, treat, discharge or refer patients with a
defined list of conditions as appropriate.4–6 One
condition typically included in such guidelines is
hypoglycaemia in diabetes.
This review focuses on patients with type II
diabetes who are prescribed oral hypoglycaemic
agents (OHA). OHA are used to treat some
patients with type II diabetes when there is either
insulin resistance or when the pancreas produces
insufficient quantities of insulin to meet the body’s
requirements.7 8 In the latter, their action stimu-
lates the secretion of stored insulin from pancreatic
beta cells, which then acts at a cellular level
enabling the uptake and utilisation of glucose by
the cell.8 Recurrent and prolonged hypoglycaemia
resulting from renal insufficiency, drug interaction
or accidental/deliberate overdose are known risks
of OHA, particularly the sulphonylurea group.7–9 In
the prehospital setting a post-hypoglycaemic
patient may be discharged by the ambulance
clinician after apparent recovery, only to have a
subsequent event hours or even days later. These
risks have resulted in some,5 10–13 but not all,4 14
ambulance services advising transportation to
hospital for all post-hypoglycaemic patients with
type II diabetes treated with OHA, regardless of
treatment response. Such service variation high-
lights the inconsistencies in ambulance service
hypoglycaemia guidelines both in the UK and
internationally.4 5 10–14
AIM
To determine the extent to which post-hypogly-
caemic patients with diabetes who are prescribed
OHA are at risk of repeat hypoglycaemic events
(RHE) after being treated in the prehospital
environment, and whether they should be trans-
ported to hospital regardless of their post-treat-
ment response.
METHODS
A systematic literature review was conducted. The
following search strategy was used to retrieve
relevant material: (1) Medline (using Pubmed) was
searched using the following search strategy:
(‘‘diabetes’’[All Fields] OR ‘‘diabetes mellitus’’[All
Fields] OR ‘‘diabetic’’[All Fields]) AND
((‘‘sulphonylurea’’[All Fields] OR
‘‘sulfonylurea’’[All Fields]) OR ‘‘rebound
hypoglycaemia’’[All Fields] OR ‘‘diabetic
emergency’’[All Fields] OR ‘‘oral agents’’[All
Fields] OR ‘‘oral hypoglycaemic agent$’’[All
Fields] OR (‘‘hypoglycaemia’’[All Fields] OR
‘‘hypoglycaemia’’[All Fields] OR ‘‘hypoglyc$’’[All
Fields]) OR ‘‘glucose’’[All Fields] OR
‘‘dextrose’’[All Fields] OR ‘‘glucagon’’[All Fields])
AND (‘‘pre-hospital’’[All Fields] OR
‘‘prehospital’’[All Fields] OR ‘‘ambulance’’[All
Fields] OR ‘‘paramedic’’[All Fields] OR
((‘‘therapy’’[Subheading] OR ‘‘therapy’’[All
Fields] OR ‘‘treat’’[All Fields]) AND refer[All
Fields]) OR ‘‘see and treat’’[All Fields]). (2)
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Electronic searching of the Cochrane Library and clinicaltrials.
gov using adaptations of the above search terms. (3) Hand
searching of clinical text books and key journals: BNF
pharmacology 2006; Emergency Medicine Journal (January 2000
to March 2007); Joint Royal College Ambulance Liaison
Committee National Clinical Guidelines (2006). (4) Grey
literature (unpublished material): ‘‘Pathfinder’’ course material.
(5) Personal communication with other ambulance services and
diabetologists.
Inclusion/exclusion criteria
Peer reviewed papers, letters and unpublished documents were
all included in the review. Retrieved material was excluded if it
did not include patients with type II diabetes treated with
OHA, the topic was not of direct relevance, or the paper was
not published in English.
Titles and abstracts were screened for inclusion by one of the
authors (DF). All potentially relevant papers and material were
retrieved and the full documents were then read by both
authors to check that each met the inclusion criteria. Each paper
was then categorised according to publication source and
research method (fig 1). References of electronically retrieved
but excluded papers are available from the authors on request.
ANALYSIS
Due to the small number, low quality and data heterogeneity of
included quantitative research studies a meta-analysis of the
findings was not conducted. Instead a descriptive summary of
the included paper’s sources and research design was developed
and a narrative synthesis of key themes from these papers is
provided.
Findings
Table 1 outlines the sources of literature and types of study
design of the included papers. Eighteen papers were retrieved
from peer-reviewed journals, one internet site and four
publications from other sources were also included. Only one
controlled trial was found in this area.12 Eight of the included
papers were cohort studies.6 13 15–20 Six papers were literature
reviews.8 9 21–24 Two presented case reports25 26 and one reported
a retrospective case note analysis study.14 In addition, four
guidelines4 5 10 11 and one well recognised reference book7 were
included.
Of the included studies from the retrieved literature
(n = 18), 126 12–18 22–25 included patients who had had hypogly-
caemic events and were treated with OHA. Twelve8 9 13 15–17 19 21–
25 emphasised the inherent dangers of these drugs, and
108 9 12 13 17 20–23 25 highlighted treatment in, or suggested a
treatment only available within, the hospital environment.
Care was taken to ensure no double counting of individual
studies occurred.
RESULTS
Incidence of OHA-induced hypoglycaemia
Of the included studies, which followed patients between
6 months and 3 years, the incidence of OHA-induced hypogly-
caemia (in type II diabetes) was predominantly reported as
being between 0.8% and 12%.6 15 16 21 However, one study
reported an incidence of 23% over a 3-year period.13
Risks and causes of OHA-induced hypoglycaemia
The potential for hypoglycaemia was highlighted as the most
significant risk associated with OHA.7 8 24 The primary risk to
any hypoglycaemic patient is reduced levels of consciousness,
leading to airway compromise, seizure, cerebral oedema
(potentially resulting in permanent neurological deficit) and in
rare cases, death.8 24 Other risks such as prolonged hypoglycae-
mia or RHE result from the long-acting nature of some OHA,
particularly the sulphonylurea group.8 13 24 25 Cases have been
described in which hypoglycaemic patients prescribed OHA
have been treated appropriately with intravenous glucose only
to experience RHE hours or even days after the initial event.17 25
Two reviews8 22 describe the general risk factors associated
with hypoglycaemia in patients treated with OHA. These
include the elderly, those with a history of vascular disease,
renal failure, reduced food intake, alcohol consumption and
drug interactions. Specific examples of these risk factors in the
included papers include medication interactions,8 26 quiescent
renal or hepatic disease25 and accidental or deliberate inges-
tion.8 9 Many of these arise from the clinicians’ failure to
consider the contribution of such risk factors to either an initial
or RHE and illustrate how ignoring such risk factors unnecessa-
rily exposes the patient to the dangers associated with
hypoglycaemia.
Repeat calls for hypoglycaemic events
Five of the papers included in this review directly discussed
repeat emergency calls for hypoglycaemic events.14 16–19 These
papers were examined to identify the rates of RHE and whether
OHA were viewed as a contributory factor. There was no
standard definition of ‘‘recurrence’’ in the literature. Reported
recurrence times ranged between 24 and 120 h, with the
incidence of RHE within a 48-h period varying between 2%
and 7%.14 16–19 No studies were detailed enough to determine
how many of these RHE were directly related to OHA.
Transport to hospital
Roberts and Smith23 identified post-hypoglycaemic patients
treated with OHA as high risk and recommended that they be
transported to hospital; no rationale was provided. Brackenridge
et al20 emphasise that patients on OHA are ‘‘special cases’’ (p
185) and suggest the ‘‘threshold for admission’’ (p 185) to beFigure 1 A flow chart of included literature.
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Table 1 Study design and core findings of included papers
Author, date and
country Patient group Study design Core findings and outcomes Limitations/weaknesses
Mattila et al,12 2004,
Finland
Investigation of the clinical epidemiology
of severe out-of-hospital hypoglycaemia
Control trial 90% (n = 62) of patients were left at scene Only 8.5% (n = 69) of patients left at
home were included in this study
11 months (Feb–Dec 2001)
69 Participants
55% (n = 22) of questionnaire respondents
had a RHE within 3-month follow-up period,
none within 24 h
Short study duration
The practice of leaving selected patients at the
scene after assessment and treatment was
found to be effective, safe and economical
Only patients with type 1 diabetes were
left at home
All patients with type 2 diabetes prescribed OHA
were transported to hospital
Time between emergency contact and
research contact was 3 months
Steinmetz et al,18 2006,
Denmark
Assessed patients preferences to locality
of treatment, ie, hospital or home.
Prospective
cohort study
6% (n = 8) patients treated and discharged at
the scene were admitted to hospital within 48 h
This intervention was limited to
physicians
139 Participants Involvement of OHA is unknown Did not provide sufficient detail to
determine the cause of admission for
the eight patients who were admitted
within the 48-h period
Limited information on study methods
Walker et al,6 2006, UK Evaluation of ambulance crew referral
pathway to a DSN
3 Months (Dec 2002–March 2003)
38 Participants
Prospective
cohort study
53% (n = 20) of referred patients had
medication altered, 37% (n = 14) required
ongoing review. Of participants who returned
questionnaire, 73% (n = 19) felt more able to
treat a hypoglycaemic episode in the future.
Small sample size
Recommends specialist pathways to DSN for
patients who have had a hypoglycaemic event
Required shorter follow-up period, ie,
,7 days required to ensure safety for
patients
Highlights the need for medication alteration and
expert advice for patients
Brackenridge et al,20
2006, UK
Exploration of the use of emergency
services by people with diabetes
12-Month audit (Oct 2000–Sept 2001)
89 Participants
Prospective
cohort study
Management of hypoglycaemia by the
emergency services was varied and not always
appropriate
Patients were not followed up
adequately to provide detail on, and
determine if, a repeat hypoglycaemic
event occurred
11% (n = 10) of sample were admitted to
hospital
Many patients who attend ED were discharged
with no follow-up arrangements. Education is
required for healthcare professionals. Highlights
challenges of identifying people who need to be
admitted to hospital.
States that patients treated with OHA should be
treated as ‘‘special cases’’
Cain et al,17 2003, Canada Determined the outcomes of patients
treated and not transported for
hypoglycaemia and identified criteria for
those who do not require to be
transported
Prospective
cohort study
Repeat hypoglycaemic events are reported to be
common, however, recurrences within 48 h are
not
Unable to determine OHA involvement
in recurrence of hypoglycaemia
10 Months (Aug–June 2001)
220 Participants
From the 220 hypoglycaemic emergencies, 145
patients were left at home, 27% (n = 40) of
whom made a repeat call within the study
period; 2% (n = 3) of these were within 48 h.
From the 75 patients transported to hospital,
22.7% (n = 17) reported a RHE, with 4%
(n = 3) occurring within a 48-h period.
Given the high incidence of repeat
hypoglycaemic episodes, paramedics and
physicians need to emphasise the importance of
follow-up
Holstein,13 2003,
Germany
Obtain reliable data on the care of
prehospital diabetic emergencies with a
view to improving quality of care
Prospective
cohort study
Training of emergency teams with a specific
intervention improved quality of treatment and
prognosis outcome for patients
This intervention was limited to
physicians
3 Years (Jan 1997–Dec 2000)
213 Patients
Treatment of severe hypoglycaemia at the scene
was deemed to be safe in patients with type 1
diabetes who had previously received structured
patient education
Limited number of sulfonylurea-induced
hypoglycaemia, much larger trials
including comorbidity, type of OHA and
dose would be required to substantiate
the results of this study
Mortality rates for sulfonylurea-induced
hypoglycaemia dropped from 4.9% (n = 2) to
0%
Continued
Review
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Table 1 Continued
Author, date and
country Patient group Study design Core findings and outcomes Limitations/weaknesses
Leese et al,15 2003, UK Determine the incidence, predisposing
factors and costs of emergency
treatment of severe hypoglycaemia in
people with type 1 and type 2 diabetes
Cohort study Hypoglycaemia requiring emergency assistance
is as common in patients with type 2 diabetes
as in insulin-dependent type 1 diabetes
Episodes of hypoglycaemia that were
treated in environments other than
ambulance, primary care and hospitals
were not recorded, this may have
resulted in an underestimation of all
severe hypoglycaemic events.
12-Month period (June 1997–June 1998)
160 Patients
Carter et al,19 2002,
Canada
Determine if patients who had received
prehospital iv dextrose seek additional
medical care within a 72-h period post-
hypoglycaemic event
Retrospective
cohort study
68% Refused transportation Hawthorne effect: as paramedics were
aware that this study was taking place
the potential for such an effect cannot
be excluded
12 Months (April 1999 to March 2000) The practice of treating patients with
symptomatic hypoglycaemia and leaving them
at the scene appears to be safe. Further study
required to confirm this.
100 Patients
Socransky et al,16 1998,
USA
Aimed to identify RHE in patients with
diabetes and compare outcomes of those
who refused with those who were
transported to hospital
Cohort study Out-of-hospital treatment of hypoglycaemic
patients with diabetes appears to be effective
and efficient independent of whether they were
transported or not
Did not consider clinic visits as an
indicator of relapse, which may result in
an underestimation of relapses
7 Months (Jan–July 1995) Relapse rates did not differ significantly
between the refusers and the transported
patients
374 Participants (made 571 emergency
calls)
None of the 32 patients who relapsed did so
within the subsequent 48 h
Langford et al,25 2003, UK Case report describing repeat
hypoglycaemic events in a 62-year-old
woman with impaired renal function
treated with gliclazide
Case report Demonstrates the effects impaired renal function
have on plasma insulin concentrations in a
patient who is treated with OHA. The patient
had repeat hypoglycaemic events.
Single case
Bussing and Gende,26
2002, USA
Two case reports highlighting the
interaction between clarithromycin and
sulfonylureas resulting in hypoglycaemia
Case report Both patients received an initial bolus of iv
glucose. The patient who did not receive a
continuous glucose infusion had a repeat
hypoglycaemic event.
Only two cases
Anderson et al,14 2002,
Denmark
Aimed to validate the appropriateness of
leaving the patient with prehospital
hypoglycaemia after being safely treated
at home in a physician-based EMS
system
Retrospective
case note
analysis
964 Patients were released home This intervention was limited to
physicians
4 Years (1995–8) RHE events between 0 and 72 h post-treatment
were identified. 5% (n = 46) of those treated
and released home experienced a RHE within
the 72-h period, 75% (n = 31) occurring within
48 h post-treatment.
1148 Hypoglycaemic patients treated by
a mobile intensive care unit were used
Possible predictors of transportation
were identified
Zammitt and Frier,24
2005, UK
Aimed to identify the frequency and
pathophysiology of hypoglycaemia in
type 2 diabetes
Systematic
literature review
Results suggest that insufficient and misleading
information may have contributed to the
perception that hypoglycaemia is considered to
be a mild and infrequent side effect of treatment
in type 2 diabetes. Identifies sulfonylurea-
induced hypoglycaemia as a significant problem.
Narrative synthesis of findings, not
meta-analysed
Search via PubMed 1984–2005 Variations in design, heterogeneity of
study populations and varying
classifications of hypoglycaemia.
Looking at the elderly patients with
type 2 diabetes with hypoglycaemic
events confounded attempts in this
review to determine the frequency of
hypoglycaemia in type 2 diabetes.
Roberts and Smith,23
2003, UK
Identified outcomes for patients who
were treated for hypoglycaemia out of
hospital and included set of
recommendations for the safe follow-up
of patients
Systematic
literature review
Advised transportation to hospital of all post-
hypoglycaemic patients treated with OHA, no
rationale was provided
Narrative synthesis of findings, not
meta-analysed.
Search strategy was defined using MeSH
terms and conducted via Medline
Search terms do not include
hypoglycaemia or other condition-
specific terms
Limited retrieval of papers
Continued
Review
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low, while Socransky et al16 state that patients taking OHA who
have had a hypoglycaemic event should be convinced to travel
to hospital. The British National Formulary (BNF)7 recommends
that such patients should always be treated in hospital. A recent
review9 supports this stance and recommends patients are
observed for at least 24 h; whereas less conservatively, Harrigan
et al8 suggest a minimal observation time of 8 h. The length of
time patients should be observed, therefore, remains unclear.
The reviews by Murphy and Colwell22 and Harrigan et al8 reveal
the dangers of hypoglycaemia caused by OHA and highlight
treatments such as continuous glucose infusions and constant
blood glucose monitoring. A strong case for such treatments and
transportation of patients with OHA-induced hypoglycaemia is
demonstrated in the study by Holstein et al,13 in which the
authors specifically targeted sulphonylurea-induced hypoglycae-
mic patients with a treatment protocol. This consisted of
mandatory additional glucose infusions and hospital admission
for further treatment and observation. The study’s pre-interven-
tion statistics on mortality rates associated with all sulphony-
lurea-induced hypoglycaemia were 4.9% and 1.7% for all other
causes. After intervention, mortality rates from severe hypogly-
caemia caused by sulphonylureas were reduced to 0%.
DISCUSSION
This systematic review has retrieved and analysed 23 docu-
ments in an attempt to establish if post-hypoglycaemic patients
with diabetes who are prescribed OHA are at risk of RHE after
being treated in the prehospital environment and whether such
patients should be transported to hospital regardless of
treatment response.
Risks associated with OHA
Although a relatively rare occurrence, patients with diabetes
treated with OHA can and do experience hypoglycaemic
episodes. This review clearly exposes the risks associated with
OHA and the possible dangers of RHE when leaving post-
hypoglycaemic patients treated with OHA at home.7 8 20 23 25 26 A
decision not to transport these patients may result in
unnecessary and unacceptable risks, including repeat or
prolonged hypoglycaemia leading to seizure, cerebral oedema,
permanent neurological deficit and, rarely, death.8 9
Repeat calls and OHA
It cannot be determined from the five papers14 16–19 documenting
repeat call-outs if OHA were directly involved, but it is evident
Table 1 Continued
Author, date and
country Patient group Study design Core findings and outcomes Limitations/weaknesses
Spiller,9 1998, USA Focuses on antidiabetic medications in
overdose (deliberate and accidental)
Systematic
literature review
Overdose with antidiabetic drugs produces
major morbidity, requires intensive care
medicine and prolonged hospital stays
No search strategy defined, difficulty in
reproducing review
Monitored for at least 24 h Narrative synthesis of findings, not
meta-analysed
When overdose does occur prompt recognition
results in an improvement in successful
outcomes
Harrigan et al,8 2001,
USA
Review of oral antidiabetic agents
describing the treatment of type 2
diabetes regarding the pharmacology,
toxicity and treatment
Review Pharmacology of OHA described, adverse
effects, ie, hypoglycaemia, drug interactions and
toxicities
Search strategy is not defined, difficulty
in reproducing review
Patients with hypoglycaemia in the setting of
therapeutic error, impaired renal function etc
should be admitted for observation
Murphy and Colwell,22
2000, USA
An educational review that details the
pathophysiology of the condition as well
as treatments and emergencies relating
to the condition
Review Describes prehospital treatment for diabetes-
related emergencies. Prolonged hypoglycaemia
in patients treated with OHA is highlighted.
Search strategy is not defined, difficulty
in reproducing review. Some of the
treatments are either specific to region
or dated.
Patients on OHA are at risk of prolonged
hypoglycaemia
Lheureux et al,21 2005,
Belgium
Focuses on the antidotal treatment of
sulfonylurea-induced hypoglycaemia with
octreotide
Review Hypoglycaemia is a major potential adverse
effect of sulfonylurea agents. Causes and
treatments are described, specifically the use of
octreotide. Clearly describes pharmacological
actions of sulfonylureas.
Limited number of studies on the use of
octreotide in sulfonylurea-induced
hypoglycaemia. Search strategy not
defined.
Basics,10 Pathfinder
guidelines, 2004, UK
n/a Guideline Advises transportation of all post-
hypoglycaemic patients with diabetes treated
with OHA to hospital
n/a
Welsh Ambulance
Service,5 T&R guidelines,
2006, Wales
n/a Guideline Advises transportation to hospital for patients
treated with OHA who have experienced a
hypoglycaemic event
n/a
Joint Royal College
Ambulance Liaison
Committee,11 2006, UK
n/a Guideline Advises that all patients treated with OHA who
have experienced a hypoglycaemic event should
be transported to hospital
n/a
Scottish Ambulance
Service,4 T&R guideline,
2004, Scotland
n/a Guideline Does not specifically advise transportation to
hospital for patients treated with OHA who have
experienced a hypoglycaemic event
n/a
British National
Formulary,7 2006, UK
n/a n/a The BNF provides specific detail on
sulphonylurea-induced hypoglycaemia and
highlights the prolonged effects and the need for
treatment in hospital
n/a
BNF, British Nationial Formulary; DSN, diabetic specialist nurse; ED, emergency department; EMS, emergency medical services; iv, intravenous; OHA, oral hypoglycaemic agent;
RHE, repeat hypoglycaemic event; T&R, treat and refer.
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that unrecognised risks, such as those outlined in the study by
Harrigan et al8 and failure to treat accordingly may lead to a
RHE posing a direct risk to patients. Repeat calls also directly
impact on ambulance resources reducing ambulance availability
and consequently affecting response times. On the basis of the
limited available evidence, the safest action to be taken by
ambulance clinicians attending a post-hypoglycaemic patient
with diabetes treated with OHA is to transport them to
hospital to be admitted for a period of observation, appropriate
treatment and follow-up care. The potential benefits of
admission may include extended monitoring, continuous
glucose infusions, pharmacological interventions, exploration
of underlying causes and medication alteration if required. In
the UK the standard prehospital treatment for hypoglycaemia
includes either intramuscular glucagon or the intravenous
administration of 10% glucose, in 100 ml boluses to a maximum
of 300 ml (30 g).11 Similar guidelines to those used in the study
by Holstein et al,13 ie, continuous infusion of 10% glucose after
the initial bolus, could be considered for UK ambulance
clinicians. This may be particularly beneficial in remote and
rural areas, should such a situation arise, where transportation
times can be prolonged and repeat intervention may be
required.
Future directions: education and referral processes
Some ambulance service guidelines currently enable clinicians to
refer or discharge patients with certain conditions, including
hypoglycaemia. However, although basic ambulance service
education includes the recognition of and emergency treatments
for patients with hypoglycaemia, there is little specific educa-
tion on the risks associated with OHA or the provision of
appropriate care plans (ie, what to do with patients). Lack of
awareness of the possibility of a RHE may result in patients
being left at home inappropriately by ambulance clinicians. The
literature currently suggests a minimum observation period of
24 h for post-hypoglycaemic patients treated with OHA.
Extended observation would be difficult in an outpatient
setting, the literature did not suggest this as an alternative
and it is unlikely that the current health service infrastructure
would enable this to be achieved safely. Therefore, patients
treated with OHA who have had hypoglycaemic events
requiring treatment from an ambulance clinician should be
transported directly to hospital so they can be observed, treated
and receive appropriate follow-up care. Ambulance clinicians
should be educated to this effect.
Although it is not always necessary to transport the post-
hypoglycaemic type 1 insulin-dependent patient with diabetes,
this review has highlighted other issues that require to be
addressed with this population. Some S&T guidelines place the
responsibility of contacting the general practitioner following a
hypoglycaemic event on the patient;4 ambulance clinicians
typically leave a carbon copy of the S&T form containing details
of the event and the patient is asked to pass this on to their
general practitioner. This system is ineffective. Patients’
attendance for follow-up in primary care (which enables
medication alteration and specialist education to be provided)
is low,17 and when patients do make an appointment the time
delay between the original referral and attendance can often be
several days, during which time a relapse may occur.6 Walker et
al6 developed and evaluated a referral process for post-
hypoglycaemic patients. Patients who had had a hypoglycaemic
episode were referred by the ambulance service to a diabetic
specialist nurse (DSN) who then contacted the patient within
7 days of the event. Fifty-three per cent (n = 20) of the
referred patients required medication alteration and 37%
(n = 14) required additional appointments for ongoing care
issues. One patient had a further hypoglycaemic event in the
period between being referred and being seen by the DSN.
Irrespective of the type of diabetes, efforts should be made to
increase the attendance of these patients to primary or specialist
care within as short a timeframe as possible. This would enable
more patients to receive expert advice, medication review and
subsequent follow-up care. Evidence-based interventions to
increase post-hypoglycaemic patient attendance in primary care
should be developed.
LIMITATIONS
Only English language publications were included in this
review. Although we have comprehensively searched and
appraised the available literature, little high quality research
was retrieved. Consequently, caution is required in interpreting
the findings of the studies.
CONCLUSION
The findings of this study indicate that post-hypoglycaemic
patients treated in the prehospital environment are at a 2–7%
risk of experiencing a RHE within 48 h. The potential for OHA
to cause RHE is highlighted in the reviewed literature. However,
the extent to which this occurs in practice remains unknown.
This lack of evidence has led to the recommendation that
conservative management, through admission to hospital, is
appropriate. The review has also highlighted that appropriate
follow-up care of all other post-hypoglycaemic patients is
required.
Several practice and research recommendations arise from
this review.
Practice recommendations:
c All hypoglycaemia S&T guidelines should recommend that
patients treated with OHA are transported to hospital for
appropriate observation and treatment. Ambulance clin-
icians should receive education on the appropriate manage-
ment of hypoglycaemic patients treated with OHA.
c Referral pathways should be developed to ensure appro-
priate follow-up care for all patients with diabetes.
Research recommendations:
c Evidence-based interventions to increase post-hypoglycae-
mic patient attendance in primary care should be developed
and evaluated.
c An investigation into the causes of RHE, the timeframes in
which these occur and the length of observation time
required to ensure patient safety.
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